Japan Updates JPMA Self-Inspection Checklist for Quality Testing in New Drug Applications

Details of the Update

The updated checklist replaces the previous document-based conformity inspection checklist and consolidates analytical testing and stability testing into a single unified framework. This integration is intended to streamline how applicants assess and demonstrate the reliability of quality data in regulatory submissions. 

The revision explicitly removes non-clinical study elements, narrowing the checklist’s scope to focus on quality testing relevant to product approval. It also clarifies that the checklist is not a prescriptive list of required documents, but rather a tool designed to support overall reliability assessment of submitted data. 

Additionally, the checklist emphasizes that applicants must ensure the preparation, conduct, and documentation of tests meet established reliability standards. For contracted testing, applicants are required to maintain documented methods to confirm test reliability, reinforcing accountability even when outsourcing. 

The update further highlights the importance of electronic records compliance, requiring adherence to established procedures, including those aligned with electronic records and electronic signatures guidelines. 

The JPMA notes that ongoing revisions are expected as industry practices continue to evolve. 

Why It Matters

This update improves regulatory clarity by consolidating quality testing expectations into a single framework and removing non-relevant elements. It supports digital alignment through clearer expectations for electronic records and enhances operational efficiency by simplifying self-inspection processes. At the same time, it maintains a non-prescriptive approach, minimizing unnecessary compliance burden while ensuring data reliability. 

Who This Affects

This update is relevant for quality assurance (QA), regulatory affairs (RA), and R&D teams within pharmaceutical companies preparing new drug applications in Japan, particularly those involved in quality testing, data integrity, and submission readiness.

Next Steps

Organizations should review and update internal quality testing procedures and self-inspection practices to align with the revised checklist. Teams should also evaluate current documentation workflows to ensure that scientific validity, data integrity, and reliability standards are consistently met. Cross-functional coordination between QA, RA, and R&D will be essential to ensure full alignment with the updated framework. 

As regulatory expectations around data reliability and digital compliance continue to evolve, solutions like RegASK can support organizations in staying ahead. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now. 

FAQs

What is the JPMA self-inspection checklist for quality testing? 

It is a tool published by the Japan Pharmaceutical Manufacturers Association (JPMA) to help applicants assess the reliability and scientific validity of quality test data submitted in new drug applications.

What are the key updates in the revised checklist? 

The checklist now integrates analytical and stability testing, removes non-clinical study elements, and emphasizes data reliability, documentation standards, and electronic records compliance. 

Does the checklist specify required submission documents? 

No. The checklist is not prescriptive and does not define a fixed list of required documents. It is intended to support overall reliability assessment. 

How can RegASK help with compliance under this update? 

RegASK helps organizations monitor evolving regulatory expectations, align internal processes with updated frameworks, and ensure data integrity and submission readiness through AI-driven regulatory intelligence and workflow automation.